Explore the categories so you can find more about your search.
Categorie > Multiple Sclerosis
Promising Results In First Blinded Study Of Venous Insufficiency Prevalence In Multiple Sclerosis
Categorie : Multiple SclerosisMore than 55 percent of multiple sclerosis patients participating in the initial phase of the first randomized clinical study to determine if persons with MS exhibit narrowing of the extracranial veins, causing restriction of normal outflow of blood from the brain, were found to have the abnormality ...
read more 
Fri Mar 2010
Preliminary CCSVI Results Announced - Multiple Sclerosis Society
Categorie : Multiple SclerosisResearchers who have carried out the first randomized clinical study to determine if people with multiple sclerosis (MS) show signs of narrowing of the veins causing restricted blood flow from the brain have said they are 'cautiously optimistic' following the release of preliminary results. The Uni ...
read more Fri Mar 2010
Blocking Cell Movement For Cancer, MS Treatment
Categorie : Multiple SclerosisUniversity of Adelaide researchers in Australia are finding new ways to block the movement of cells in the body which can cause autoimmune diseases and the spread of cancer. Led by Professor of Immunology Shaun McColl, the researchers have identified molecular "receptors" on the surface of cells wh ...
read more Fri Mar 2010
MS Society Launches Major Manifesto Campaign, UK
Categorie : Multiple SclerosisToday the MS Society launches its 2010 Manifesto in a serious and high profile attempt to encourage the next Government to act upon MS inequalities. The document sets 10 powerful calls for the next Government to act upon... ...
read more Fri Mar 2010
Add-On Daclizumab Treatment May Be Better In Reducing Multiple Sclerosis Disease Activity Than Interferon Beta Alone
Categorie : Multiple SclerosisAn article published Online First and in the April edition of The Lancet Neurology reports that add-on daclizumab treatment might reduce multiple sclerosis disease activity more than standard interferon beta treatment alone. The article is the work of Dr John W Rose, Neurovirology Research Laborator ...
read more Fri Mar 2010
Copaxone(R) 15-Year Study In Multiple Sclerosis Patients Demonstrates Robust Long-Term Efficacy And Safety
Categorie : Multiple SclerosisTeva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced the publication of data from the 15-year clinical study with Copaxone® (glatiramer acetate injection), which is the longest prospective and continuous evaluation ever conducted in relapsing-remitting multiple sclerosis (RRMS) patients. Th ...
read more Fri Mar 2010
Exercise Helps Protect Brain Of Multiple Sclerosis Patients
Categorie : Multiple SclerosisHighly fit multiple sclerosis patients perform significantly better on tests of cognitive function than similar less-fit patients, a new study shows. In addition, MRI scans of the patients showed that the fitter MS patients showed less damage in parts of the brain that show deterioration as a result ...
read more Fri Mar 2010
Success For Pilot Scheme - Multiple Sclerosis Society
Categorie : Multiple SclerosisAn innovative scheme piloted in Surrey and Sussex, the first of its kind in the country, has had an overwhelmingly positive impact on the lives of people in the area with multiple sclerosis (MS)... ...
read more Fri Mar 2010
LDN Phase II Trial Results Published - Multiple Sclerosis Society
Categorie : Multiple SclerosisResults of a phase II clinical trial on the safety and effectiveness of low dose naltrexone (LDN) as a symptom-relief treatment for people with MS have been published in the journal Annals of Neurology. The results of the study suggest that LDN is safe and may have positive effects on the mental qu ...
read more Fri Mar 2010
Regis Technologies Passes FDA Pre-Approval Inspection For Acorda Therapeutics' Approved Multiple Sclerosis Drug, Ampyra™
Categorie : Multiple SclerosisRegis Technologies, Inc., a leading provider of cGMP and non-GMP synthesis and separations services for active pharmaceutical ingredients (APIs) and intermediates, announced it has received an Establishment Inspection Report (EIR) from the U.S... ...
read more Wed Feb 2010
3-Year Mission To Understand And Treat Neurodegenerative Disease
Categorie : Multiple SclerosisProject A.L.S. (New York, NY) and the Robert Packard Center for ALS Research at Johns Hopkins University (Baltimore, MD) announced that they will partner on P2 ALS, a $15 million initiative designed to advance ALS (Lou Gehrig's disease) research exponentially over the next three years. Project A.L.S ...
read more Wed Feb 2010
MS Society Calls On Stem Cell Researchers For Grant Applications
Categorie : Multiple SclerosisThe MS Society has called for researchers and scientists to come forward with research projects investigating the potential benefit of stem cells in multiple sclerosis (MS). A new partnership between the MS Society and the UK Stem Cell Foundation has levered £1million to be specifically ring-fen ...
read more Wed Feb 2010
Multiple Sclerosis: Blacks Have More Severe Symptoms, Decline Faster Than Whites, New Study Shows
Categorie : Multiple SclerosisFewer African Americans than Caucasians develop multiple sclerosis (MS), statistics show, but their disease progresses more rapidly, and they don't respond as well to therapies, a new study by neurology researchers at the University at Buffalo has found... ...
read more Wed Feb 2010
The Season Affects Multiple Sclerosis Risk
Categorie : Multiple SclerosisPrevious studies have shown multiple sclerosis (MS) patients are more often born in spring than in any other season, indicating that there is an environmental risk factor for the disease. A paper in the journal Neurology, reviewed for f1000 Medicine by Emmanuelle Waubant and Ellen Mowry, now suggest ...
read more Wed Feb 2010
Drinking Milk During Pregnancy May Lower Baby's Risk Of MS
Categorie : Multiple SclerosisDrinking milk during pregnancy may help reduce your baby's chances of developing multiple sclerosis (MS) as an adult, according to a preliminary study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010... ...
read more Wed Feb 2010
New Study Finds Specialized Support Programs Can Increase Treatment Adherence And Persistence, Reduce Relapses For People With Multiple Sclerosis
Categorie : Multiple SclerosisA new study reveals that multiple sclerosis (MS) patients enrolled in a seven-month disease therapy management (DTM) program show greater adherence to injectable MS medications and treatment persistence than patients who receive injectable MS medications through a community pharmacy... ...
read more Wed Feb 2010
MP Argues Risk Sharing Scheme Not Fit For Purpose
Categorie : Multiple SclerosisJames Gray MP has argued the Risk Sharing Scheme has 'fatal flaws' and is 'hopelessly out of date'. James Gray MP, Chair of the All Party Parliamentary Group on MS, secured a debate on the Risk Sharing Scheme on Tuesday of this week. The purpose of the debate was to consider whether the Scheme has w ...
read more Wed Feb 2010
Elan Drug Technologies Welcomes The NDA Approval Of MS Drug AMPYRA™ (Dalfampridine) Extended Release Tablets
Categorie : Multiple SclerosisElan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) today issued the following statement regarding the U.S. Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstra ...
read more Thu Jan 2010
Drug That Helps Improve Walking Speed Approved In US
Categorie : Multiple SclerosisThe US Food and Drug Administration (FDA) has approved a drug which has been found to allow people with multiple sclerosis (MS) to walk faster. People treated with the drug Ampyra (dalfampridine) were found in clinical trials to have faster walking speeds than those treated with a placebo, the Ameri ...
read more Thu Jan 2010
European Drugs Watchdog Finds Benefits Of Tysabri Continue To Outweigh Risks
Categorie : Multiple SclerosisThe European Medicines Agency (EMA) has finalised a review of Tysabri (natalizumab) and the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus. The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the risk of dev ...
read more Thu Jan 2010
